These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21955979)

  • 1. Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis.
    Senel S; Cobankara V; Taskoylu O; Guclu A; Evrengul H; Kaya MG
    J Investig Med; 2011 Dec; 59(8):1273-5. PubMed ID: 21955979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab in two patients with juvenile ankylosing spondylitis.
    Schmeling H; Horneff G
    Rheumatol Int; 2004 May; 24(3):173-6. PubMed ID: 14648110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D
    Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab: in ankylosing spondylitis.
    Robinson DM; Keating GM
    Drugs; 2005; 65(9):1283-91; discussion 1292-4. PubMed ID: 15916451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Filippatos TD; Vasakos S; Nikas SN; Drosos AA
    J Rheumatol; 2006 May; 33(5):921-3. PubMed ID: 16541480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A short-term efficacy and safety study of infliximab in active ankylosing spondylitis].
    Huang F; Zhang LY; Zhang JL; Zhang FC; Liang DF; Deng XH; Guo JH; Zhu J; Zhao W; Li XF; Hou Y
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):122-6. PubMed ID: 16624120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.
    van der Heijde D; Han C; DeVlam K; Burmester G; van den Bosch F; Williamson P; Bala M; Han J; Braun J
    Arthritis Rheum; 2006 Aug; 55(4):569-74. PubMed ID: 16874778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
    Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
    Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.